Regulatory Tracker
US regulatory status for all 94 peptides in the database.
Last updated: May 2026. Regulatory landscapes change — verify current status with FDA.gov.
16
FDA Approved
2
503A Listed
4
Restricted
72
Research Only
🚨
Breaking: FDA Moves to Reverse Peptide Ban (May 2026)
RFK Jr. announced FDA will remove 14 peptides from its do-not-compound list. A formal PCAC review of BPC-157, KPV, TB-500, MOTS-C, Semax, Emideltide, and Epitalon is scheduled for July 23–24, 2026. Regulatory statuses below will be updated following PCAC findings. Full analysis →
⚠️
GLP-1 Compounding Update (2024)
FDA removed semaglutide and tirzepatide from shortage lists in October 2024. Compounding of these drugs is now federally prohibited for 503A pharmacies. Enforcement is ongoing. Read full analysis →
FDA Approved — Full FDA approval; prescribable for approved indications; off-label use at practitioner discretion
| Peptide | Brand Name(s) | Indication | Evidence |
|---|---|---|---|
| Bremelanotide | Vyleesi, PT-141 (precursor peptide) | Hypoactive sexual desire disorder (HSDD) in premenopausal women | Strong Evidence |
| Desmopressin | DDAVP, 1-Desamino-8-D-arginine vasopressin | FDA-approved (multiple formulations: intranasal, oral, injectable); not on 503A restricted list | Strong Evidence |
| Exenatide | Byetta, Bydureon BCise | FDA approved — Byetta (twice daily), Bydureon (weekly ER) | Strong Evidence |
| Gonadorelin | GnRH, Luteinizing hormone-releasing hormone (LHRH) | FDA approved (Factrel). 503A listed for compounding. | Strong Evidence |
| Liraglutide | Victoza, Saxenda | FDA approved — Victoza (T2D), Saxenda (obesity) | Strong Evidence |
| Melanotan I | MT-1, Afamelanotide | FDA approved as Scenesse (afamelanotide) for EPP | Strong Evidence |
| Oxytocin | Syntocinon, Pitocin | FDA approved (Pitocin, Syntocinon) for obstetric use | Strong Evidence |
| Pramlintide | Symlin, Pramlintide acetate | FDA approved as Symlin (T1D and T2D adjunct) | Strong Evidence |
| PT-141 | Bremelanotide, Vyleesi | FDA approved as Vyleesi for HSDD in premenopausal women | Strong Evidence |
| Semaglutide | Ozempic, Wegovy | FDA approved — Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D) | Strong Evidence |
| Sermorelin | GHRH 1-29, GRF 1-29 | FDA-approved for pediatric GH deficiency; compounded for adult anti-aging use under 503A | Moderate Evidence |
| Tesamorelin | Egrifta, Egrifta SV | FDA approved as Egrifta SV for HIV-associated lipodystrophy | Strong Evidence |
| Thymosin Alpha-1 | Tα1, Thymalfasin | Approved in 35+ countries (Zadaxin). 503A listed for US compounding. | Strong Evidence |
| Tirzepatide | Mounjaro, Zepbound | FDA approved — Mounjaro (T2D), Zepbound (obesity) | Strong Evidence |
| Triptorelin | Trelstar, Decapeptyl | FDA approved (Trelstar) for prostate cancer and other indications | Strong Evidence |
| Ziconotide | Prialt, SNX-111 | FDA approved as Prialt (intrathecal use only) | Strong Evidence |
503A Listed — Available through 503A compounding pharmacies with valid prescription
Restricted — Previously available through compounding but now restricted; check current FDA guidance
| Peptide | Primary Uses | Evidence |
|---|---|---|
| Cerebrolysin | Alzheimer's disease, Vascular dementia | Preliminary |
| CJC-1295 | GH stimulation, Muscle gain | Moderate Evidence |
| Cortexin | Neuroprotection, Cognitive impairment | Preliminary |
| Ipamorelin | GH stimulation, Fat loss | Moderate Evidence |
Research Only — Not approved; not on 503A list; legally sold for research; human use is not FDA-authorized
| Peptide | Primary Uses | Evidence | Risk |
|---|---|---|---|
| 5-Amino-1MQ | Fat loss, Metabolic optimization | Preliminary | low |
| AHK-Cu | Hair growth, Hair loss prevention | Preliminary | low |
| Alamandine | Cardiovascular protection, Anti-fibrotic | Preliminary | low |
| Alpha-MSH | Anti-inflammatory, Melanogenesis | Moderate Evidence | low |
| Angiotensin (1-7) | Cardiovascular protection, Anti-hypertension | Moderate Evidence | low |
| AOD-9604 | Fat metabolism, Weight loss | Preliminary | unknown |
| ARA 290 | Neuroprotection, Diabetic neuropathy | Preliminary | unknown |
| Argireline | Expression lines, Wrinkle reduction | Moderate Evidence | low |
| BPC-157 | Gut healing, Tendon repair | Moderate Evidence | low |
| Cagrilintide | Weight management, Metabolic syndrome | Preliminary | unknown |
| Carnosine | Anti-glycation, Antioxidant | Moderate Evidence | low |
| Cathelicidins | Antimicrobial, Innate immunity | Moderate Evidence | low |
| CGRP | Migraine pathophysiology, Vasodilation | Strong Evidence | low |
| Cholecystokinin | Satiety signaling, Digestive enzyme release | Strong Evidence | low |
| CJC-1295 No DAC | Growth hormone secretion, Body composition | Moderate Evidence | low |
| Cortagen | Cardiovascular protection, Heart aging | Preliminary | unknown |
| Davalintide | Weight loss, Obesity | Preliminary | moderate |
| Defensins | Innate immunity, Antimicrobial | Moderate Evidence | low |
| Dihexa | Cognitive enhancement, Neurogenesis | Preliminary | unknown |
| DSIP | Sleep induction, Stress modulation | Preliminary | unknown |
| Epithalon | Telomere elongation, Anti-aging | Preliminary | unknown |
| Follistatin | Myostatin inhibition, Muscle growth | Preliminary | unknown |
| Foxo4-DRI | Senolysis, Senescent cell clearance | Preliminary | unknown |
| Fragment 176-191 | Fat loss, Lipolysis | Preliminary | low |
| Ghrelin | Educational reference, Appetite stimulation | Strong Evidence | low |
| GHRP-2 | GH secretagogue, Body composition | Preliminary | unknown |
| GHRP-6 | GH secretagogue, Muscle building | Preliminary | unknown |
| GLP-1 (Native) | Educational reference, Incretins physiology | Strong Evidence | low |
| Hexarelin | GH secretagogue, Cardioprotection | Preliminary | unknown |
| Humanin | Neuroprotection, Anti-aging | Preliminary | unknown |
| IGF-1 (Native) | Educational reference, GH axis physiology | Strong Evidence | low |
| IGF-1 DES | Local muscle growth, Tissue-specific anabolic | Preliminary | high |
| IGF-1 LR3 | Muscle growth, Tissue repair | Preliminary | high |
| Kisspeptin | Reproductive hormone regulation, GnRH stimulation | Moderate Evidence | low |
| Kisspeptin-10 | LH/FSH stimulation, Male testosterone | Preliminary | low |
| Klotho Peptide Fragments | Anti-aging, Cognitive enhancement | Preliminary | unknown |
| KPV | Gut inflammation, Anti-inflammatory | Preliminary | unknown |
| Larazotide | Celiac disease, Intestinal permeability | Preliminary | low |
| Leuphasyl | Expression line reduction, Enkephalin-based wrinkle treatment | Preliminary | low |
| LL-37 | Antimicrobial, Wound healing | Preliminary | unknown |
| Mastoparan | Antimicrobial, Mast cell activation | Preliminary | high |
| Matrixyl | Collagen stimulation, Anti-aging | Moderate Evidence | low |
| Melanotan II | Tanning, Sexual arousal | Preliminary | high |
| MK-677 (Ibutamoren) | GH secretagogue, Muscle mass | Preliminary | unknown |
| MOTS-c | Mitochondrial health, Metabolic health | Preliminary | unknown |
| Myostatin Inhibitor Peptides | Myostatin inhibition, Muscle growth | Preliminary | unknown |
| N-Acetyl Selank | Anxiolytic, Cognitive enhancement | Preliminary | low |
| N-Acetyl Semax | Cognitive enhancement, Neuroprotection | Preliminary | low |
| NAD+ | Cellular energy metabolism, DNA repair | Moderate Evidence | low |
| NNMT (Nicotinamide N-Methyltransferase) | Metabolic optimization, Fat loss target | Preliminary | low |
| Orforglipron | Weight loss, Type 2 diabetes | Moderate Evidence | moderate |
| P21 Peptide | Cognitive enhancement, Neurogenesis | Preliminary | unknown |
| Palmitoyl Tripeptide-1 | Collagen synthesis stimulation, Anti-wrinkle | Moderate Evidence | low |
| Palmitoyl Tripeptide-5 | Collagen synthesis stimulation, Anti-wrinkle | Moderate Evidence | low |
| PEGylated MGF | Muscle repair, Post-workout recovery | Preliminary | moderate |
| Pentadeca Arginate | Gut healing, Tissue repair | Preliminary | unknown |
| Pinealon | Neuroprotection, Circadian rhythm | Preliminary | unknown |
| Retatrutide | Obesity, Type 2 diabetes | Preliminary | unknown |
| Selank | Anxiolytic, Cognitive enhancement | Preliminary | unknown |
| Semax | Neuroprotection, Cognitive enhancement | Preliminary | unknown |
| SHLP2 | Insulin sensitization, Anti-apoptotic | Preliminary | unknown |
| SHLP3 | Mitochondrial protection, Retinal neuroprotection | Preliminary | unknown |
| SHLP6 | Mitochondrial cytoprotection, Cancer-selective apoptosis | Preliminary | unknown |
| SNAP-8 | Expression line reduction, Neuromuscular relaxation | Preliminary | low |
| Spadin | Antidepressant, TREK-1 antagonism | Preliminary | unknown |
| SS-31 (Elamipretide) | Mitochondrial cardioprotection, Heart failure | Preliminary | unknown |
| TB-500 | Wound healing, Muscle repair | Moderate Evidence | low |
| Thymalin | Immune modulation, Anti-aging | Preliminary | unknown |
| Thymosin Beta-4 | Tissue repair, Wound healing | Moderate Evidence | low |
| Vasoactive Intestinal Peptide | Anti-inflammatory, GI motility | Moderate Evidence | moderate |
| Vesugen | Cardiovascular health, Vascular anti-aging | Preliminary | unknown |
| Vilon | Immune modulation, Anti-aging | Preliminary | unknown |
Disclaimer: Regulatory status changes. This tracker reflects Ercle's best understanding as of May 2026. Always verify current status with FDA.gov, the 503A bulk substances list, and qualified legal/regulatory counsel before prescribing or compounding any compound.